Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
Ye Hu, Jiyue Gao, Meiling Wang, Man Li Department of Oncology & Department of Breast Surgery, The Second Hospital of Dalian Medical University, Dalian, People’s Republic of ChinaCorrespondence: Man LiDepartment of Oncology & Department of Breast Surgery, The Second Hospital of Dalian Medical...
Main Authors: | Hu Y, Gao J, Wang M, Li M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-07-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/potential-prospect-of-cdk46-inhibitors-in-triple-negative-breast-cance-peer-reviewed-fulltext-article-CMAR |
Similar Items
-
Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer
by: Yajing Huang, et al.
Published: (2020-10-01) -
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
by: Remy Thomas, et al.
Published: (2021-02-01) -
PIM-1 kinase: a potential biomarker of triple-negative breast cancer
by: Chen J, et al.
Published: (2019-08-01) -
Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
by: Yingnan Si, et al.
Published: (2021-07-01) -
Current advances in biomarkers for targeted therapy in triple-negative breast cancer
by: Fleisher B, et al.
Published: (2016-10-01)